Registered title, quoted from ClinicalTrials.gov
Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Soochow University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07652138, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
3. Subjects with Class III/IV heart failure per NYHA criteria.
Exclusion criterion 3
8. ECOG performance status score of 0 - 2.
Inclusion criterion 8
6. Serum total bilirubin < twice the upper limit of normal (ULN); serum creatinine within normal range;
Inclusion criterion 6
7. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < three times ULN.
Inclusion criterion 7
5. Subjects with a history of primary cancer, except:
Exclusion criterion 5
7. Pregnant, breastfeeding women, or those planning pregnancy in 6 months.
Exclusion criterion 9
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; earlier treatment; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07652138, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Willingness to participate in the trial and provide written informed consent.
- 2. Diagnosis of multiple myeloma (MM) per the 2017 revised WHO criteria.
- 3. BCMA-positive multiple myeloma documented at screening or in prior medical records.
- 4. Aged 18 - 70 years, any gender.
- 5. Life expectancy of at least 12 weeks.
- 6. Serum total bilirubin < twice the upper limit of normal (ULN); serum creatinine within normal range;
- 7. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < three times ULN.
- 8. ECOG performance status score of 0 - 2.
- 9. Left ventricular ejection fraction (LVEF) ≥50% with no pericardial effusion.
- 10. Ability to adhere to the study visit schedule and protocol requirements.
Exclusion Criteria:
- Patients with serious active infections.
- 2. Subjects with acquired or congenital immunodeficiency.
- 3. Subjects with Class III/IV heart failure per NYHA criteria.
- 4. Subjects with epilepsy or other central nervous system diseases.
- 5. Subjects with a history of primary cancer, except:
- Resected non-melanoma (e.g., basal cell carcinoma)
- Cured carcinoma in situ (e.g., cervical, bladder, breast cancer)
- 6. Systemic high-dose steroid use within 2 weeks before treatment.
- 7. Pregnant, breastfeeding women, or those planning pregnancy in 6 months.
- 8. Participation in other clinical trials within one month.
- 9. Major surgery within 14 days before the first study drug dose.
- 10. Any condition the investigator deems may raise subject risks or affect trial results.
Quoted from ClinicalTrials.gov, NCT07652138, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07652138, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.